Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1

Details Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1

2006-11-07

2006-11-07

Saeed, Kamal A. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S370000, C548S150000, C548S151000, C548S197000

Reexamination Certificate

active

07132436

ABSTRACT:
The present invention relates to compounds with the formula (I) and also to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11-β-hydroxysteroid dehydrogenase type 1 enzyme.

REFERENCES:
patent: 2362087 (1944-11-01), Newbery
patent: 4254260 (1981-03-01), Takaya et al.
patent: 5403857 (1995-04-01), Edwards et al.
patent: 5783597 (1998-07-01), Beers et al.
patent: 5856347 (1999-01-01), Hashiguchi et al.
patent: 5962490 (1999-10-01), Chan et al.
patent: 2003/0130258 (2003-07-01), Kurz et al.
patent: 2003/0130279 (2003-07-01), Kurz et al.
patent: 2003/0130318 (2003-07-01), Barf et al.
patent: 2003/0176476 (2003-09-01), Barf et al.
patent: 2003/0199501 (2003-10-01), Nilsson et al.
patent: 0 749 964 (1996-12-01), None
patent: 0 790 057 (1997-08-01), None
patent: 0 819 681 (1998-01-01), None
patent: 1 069 114 (2001-01-01), None
patent: 94.123 (1969-05-01), None
patent: 2 384 498 (1978-10-01), None
patent: 620654 (1940-07-01), None
patent: 822947 (1959-11-01), None
patent: 6610324 (1969-01-01), None
patent: 03173876 (1991-07-01), None
patent: 687841 (1994-03-01), None
patent: 6610324 (1967-01-01), None
patent: WO 96/04912 (1996-02-01), None
patent: WO 97/07789 (1997-03-01), None
patent: WO 98/16520 (1998-04-01), None
patent: WO 98/27081 (1998-06-01), None
patent: WO 98/36770 (1998-08-01), None
patent: WO 99/02502 (1999-01-01), None
patent: WO 99/28306 (1999-06-01), None
patent: WO 99/65884 (1999-12-01), None
patent: WO 00/02851 (2000-01-01), None
patent: WO 01/01971 (2001-01-01), None
patent: WO 01/52833 (2001-07-01), None
patent: WO 01/54691 (2001-08-01), None
patent: WO 01/90090 (2001-11-01), None
patent: WO 01/90091 (2001-11-01), None
patent: WO 02/28353 (2002-04-01), None
patent: WO 03/011258 (2003-02-01), None
Rover et al., J. Med. Chem., (1997), 40, 4378-4385.
CAPLUS, “2-Thiophenecarboxamide, N-(2,6-dimethylphenyl)-3-((phenylsulfonyl)amino)-(9CI),” Caplus Registry No. 409362-72-7.
CAPLUS, “2-Thiophenecarboxamide, N-butyl-3-(phenylsulfonyl)amino)-((CI),” Caplus Registry No. 409362-91-0.
CAPLUS, “2-Thiophenecarboxamide, N-(2-methylphenyl)-3-((phenylsulfonyl)amino)-9CI),” Caplus Registry No. 409363-32-2.
Hökfelt, Bernt, “Hypoglycemic Activity in Relation to Chemical Structure of Potential Oral Antidiabetic Substances. I. 1-Sulfonyl-3-alkylureas”,Journal of Medicinal and Pharmaceutical Chemistry, 5(1):231-257, Jan. 6, 1962.
Sonino et al., “Ketoconazole treatment in Cushing's Syndrome: Experience in 34 Patients”,Clinical Endrocrinology, 35:347-352 (1991).
Verhelst et al., “Use of ketoconazole in the treatment of a virilizing adrenocortical carcinoma”,Acta Endrocrinologica, 121:229-234 (1989).
Hisamitsu Pharmaceutical Co: “Preparation of 2-(substituted amino)thiazole derivatives as esterase inhibitors,” CAPLUS Accession No. 1995:818696, Document No. 123:228174 (1995).
Hisamitsu Pharmaceutical Co: “Preparation of 2-aminothiazole derivatives as esterase inhibitors,” CAPLUS Accession No. 1995:867676, Document No. 123:256699 (1995).
Susan Budavari et al., “The Merck Index, An Encyclopedia of Chemical, Drugs, and Biologicals, Twelfth Edition,” No. 9115, pp. 1529 (1996).
Friedrich Boberg et al., “Reaction of thioxo compounds with N-chloramidines. VI. Reaction of thioquinolone, dihydrothiazolethione and dihydroisothiazole thione with sodium N-chlorobenzenesulfonamides,” CAPLUS Accession No. 1996:420288, Document No. 125:195596 (1996).
CHEMCATS Accession No. 1998:584450, Maybridge 2000-04-03, (1998).
CHEMCATS Accession No. 1998:584451, Maybridge, 2000-04-03 (1998).
Hisamitsu Pharmaceutical Co: “Preparation of 2-(substituted amino)thiazole derivatives as esterase inhibitors,” CAPLUS Accession No. 1995:818696, Document No. 123:228174 (1995).
Asahi Chemical Ind: “Therapeutics for Alzheimer's disease containing N-(5-nitro-2-thiazolyl)benzenesulfonamides,” CAPLUS Accession No. 1996:111694, Document No. 124:165271 (1996).
Hisamitsu Pharmaceutical Co: “Preparation of diphenylthiazoles as pharmaceuticals,” CAPLUS Accession No. 1991:680016, Document No. 115:280016, (1991).
Zaki El-Hewehi et al., “Sulfonic acid derivatives: preparation and applicability as mothproofing agents,” Chemical Abstracts, vol. 58, The Abstract No. 5671, J. Prakt. Chem., pp. 297-336 (1962).
AsInEx Compound Collection, “5-Thiazolecarboxylic acid, 4-methyl-2-(((4-methylphenyl)sulfonyl)amino)-, ethyl ester,” CHEMCATS Accession No. 2001:67657, (2001).
Pharma Library Collection, “5-Thiazolecarboxylic acid, 2-(((4-chlorophenyl)sulfonyl)amino)-4-methyl-, ethyl ester,” CHEMCATS Accession No. 2001:19109, (2001).
ChemDiv, Inc. Product Library, Apr. 26, 2001, “5-Thiazolecarboxylic acid, 4-methyl-2-(((4-methylphenyl)sulfonyl)amino-), ethyl ester,” CHEMCATS Accession No. 2001:444469, (2001).
V.V. Berezhinskaya, “hypoglycemic activity in relation to chem. Structure of potential oral antidiabetic substances—(I) 1-sulfonyl-3-alkylures, (II) analogs of 1-sulfonyl-3-alkylureas, (III) 2-benzene-sulfonamido-5-alkyl-1,3,4-thiadiazole and-oxadiazoles,” CA OLD Accession No. CA57:3567g (1962).
Hans Wojahn, “Bromination of sulfapyrimidine and sulfathiazole compounds. II.,” Chemical Abstracts, vol. 51, The Abstract No. 6646d, Arch. Pharm. pp. 288, 321-336 (1955).
V.A. Krasovskii et al., “Alkylation of aminothiazoles. VII. Alkylation of 2-aminothiazole and 4-methyl-2-aminothiazole by tert-butyl alcohol,” CAPLUS accession No. 1969:115051, Document No. 70:115051, (1969).
J.D. McColl et al., “Effect of Some Sulfonylurea Deriviatives in Experimental Ulcer Formation in the Rat,” Chemical Abstracts, vol. 59, The Abstract No. 3231, Arch. Intern. Pharmacodyn, pp. 181-189 (1963).
Gaile E. Gudriniece et al., “Heterocyclic compounds based on diketones. II. 2′-Amino-5,5-dimethyl-1-cyclohexanone(2,3:4′, 5′)thiazole. I.,” Chemical Abstracts, vol. 59, The Abstract No. 6380 (1962).
Anton-Fos et al., “Pharmacological Studies of the Two New Hypoglycaemic Compounds 4-(3-Methyl-5-oxo-2-pyrazolin-1-yl)benzoic Acid and 1-(Mesitylen-2-sulfonyl)-1H-1,2,4-triazole,” Arzneim.-Forsch./Drug Res 44(11), No. 7, 1994, pp. 821-826.
Merck & Co. Inc., USA, 1999, Monograph No. 4488, “Glybuzole,” CAS Registry No. 1492-02-0.
Merck & Co. Inc., USA, 1999, Monograph No. 9084, “Sulfamethizole,” CAS Registry No. 144-82-1.
CAPLUS, “2-Thiophenecarboxamide, N-2-naphthalenyl-3-((phenylsulfonyl)amino)-(9CU)”, Caplus Registry No. 409362-65-8. (Supplement to Reference AS), 2002.
CAPLUS, “Thiophenecarboxamide, N-1-naphthalenyl-3-((phenylsulfonyl)amino)-(9CI),” Caplus Registry No. 409363-57-1. (Supplement to Reference AS), 2002.
CAPLUS, “2-Thiophenecarboxamide, 3-((phenylsulfonyl) amino)-N-(3-thienylmethyl)-(9CI),” Caplus Registry No. 409363-56-0. (Supplement to Referency AY), 1969.
CAPLUS, “2-Thiophenecarboxamide, 3-((phenylsulfonyl)amino)-N-(2-thienylmethyl)-(9CI),”, Caplus Registry No. 409362-88-5. (Supplement to Reference AS), 2002.
CAPLUS, “2-Thiophenecarboxamide, N-(2-phenylethyl)-3-((phenylsulfonyl)amino)-(9CI),”, Caplus Registry No. 409362-99-8. (Supplement to Reference AS), 2002.
CAPLUS, “2-Thiophenecarboxamide, N-(2,3-dimethylphenyl)-3-((phenylsulfonyl)amino)-(9CI),” Caplus Registry No. 409362-97-6. (Supplement to Reference AY), 1969.
CAPLUS, “2-Thiophenecarboxamide, N-(4-ethylphenyl)-3-((phenylsulfonyl)amino)-(9CI),” Caplus Registry No. 409362-93-2. (Supplement to Reference AS), 2002.
CAPLUS, “2-Thiophenecarboxamide, N-(2,6-dimethylphenyl)-3-((phenylsulfonyl)amino)-(9CI),” Caplus Registry No. 409362-72-7. (Supplement to Reference AS), 2002

Affiliated with

Also associated with

Rating

Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3663510